Clinical trial
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic…
NCT00201799 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00201799 |
|---|---|
| Title | Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation |
| Official title | Phase II Trial of Infliximab for the Prevention of Acute Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft-Versus-Host Disease |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 19 |
| Start date | Feb 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: